import { TimelineData } from "../timelineTypes";

export const zantacTimelineData: TimelineData = {
  "2025": {
    firstHalf: [
      {
        date: "January",
        text: "Judge Roberts, who oversees the Philadelphia Zantac mass tort litigation, refused to recuse himself following conflict of interest allegations.",
      },
      {
        date: "February",
        text: "Two plaintiffs claiming Zantac caused their cancer are pursuing their cases in a new state court trial.",
      },
      {
        date: "March",
        text: "A Chicago jury ruled in favor of Boehringer Ingelheim in the retrial of two Zantac cases.",
      },
      {
        date: "April",
        text: "A Maryland plaintiff alleged that ranitidine exposure between 2019 and 2020 caused prostate cancer.",
      },
      {
        date: "May",
        text: "GSK shareholders filed a lawsuit accusing the company of concealing the presence of the cancer-causing agent NDMA in Zantac.",
      },
      {
        date: "June",
        text: "Valisure filed a whistleblower lawsuit alleging GSK knew about ranitidine’s cancer risks for decades.",
      },
    ],
    secondHalf: [
      {
        date: "July",
        text: "The Delaware Supreme Court ruled that improper standards were applied for expert testimony linking ranitidine to cancer, rendering that testimony inadmissible.",
      },
      {
        date: "August",
        text: "A new Illinois trial ended with a defense verdict in a colorectal cancer claim involving Zantac.",
      },
      {
        date: "September",
        text: "More than 2,400 active MDL lawsuits were filed against Zantac manufacturers, including GSK.",
      },
      {
        date: "October",
        text: "A federal appeals court ruled that Zantac MDL cases may be reinstated after finding they were improperly dismissed.",
      },
    ],
  },

  "2024": {
    firstHalf: [
      {
        date: "January",
        text: "A Daubert hearing was held in the Delaware Zantac litigation.",
      },
      {
        date: "March",
        text: "More than 72,000 cases were consolidated in Delaware courts, representing the majority of Zantac lawsuits nationwide.",
      },
      {
        date: "June",
        text: "The Delaware Superior Court ruled that plaintiffs’ experts may testify that Zantac (ranitidine) can cause cancer.",
      },
    ],
    secondHalf: [
      {
        date: "July",
        text: "The Delaware Superior Court denied GSK’s appeal, allowing over 70,000 lawsuits to proceed.",
      },
      {
        date: "August",
        text: "An Illinois judge declared a mistrial in a prostate cancer lawsuit involving ranitidine.",
      },
      {
        date: "September",
        text: "Jury selection began in California’s first Zantac trial at Alameda County Superior Court.",
      },
      {
        date: "October",
        text: "GlaxoSmithKline (GSK) agreed to pay up to $2.2 billion to settle most Zantac-related lawsuits.",
      },
      {
        date: "November",
        text: "Plaintiffs who signed settlement agreements with GSK may receive compensation by June 2025.",
      },
      {
        date: "December",
        text: "Research indicated NDMA levels in ranitidine-containing drugs increase when exposed to heat and humidity.",
      },
    ],
  },
};
